stockrow
Saturday 7 November 2026
Export ENGN’s income statement to Excel — free account
enGene Therapeutics Inc
ENGN Healthcare Biotechnology
- EPS
- +17.5%
- Free cash flow
- +28.1%
- Total debt
- +42.1%
Quarter to July 2026, against a year earlier
1.76
0.08
+4.76%
Follow ENGN
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jul ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 6 | 6 | 37 | +158.8% | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | 0 | 0 | (100) | (55) | (117) | (131) | n/m | ||||||
| EBT margin, % | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | — | — | — | 0 | 0 | (100) | (55) | (117) | (130) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | (0.01) | 0.01 | (151.22) | (1.46) | (2.29) | (2.07) | +289.0% | ||||||
| Cash flow | — | — | — | — | — | 0.00 | (0.24) | (35.70) | (1.28) | (1.94) | (1.48) | n/m | ||||||
| Capex | — | — | — | — | — | 0.00 | 0.00 | (0.46) | (0.02) | (0.03) | (0.01) | n/m | ||||||
| Free cash flow | — | — | — | — | — | 0.00 | (0.24) | (36.16) | (1.30) | (1.97) | (1.49) | n/m | ||||||
| Book value | — | — | — | — | — | (0.14) | (1.30) | 104.60 | 7.22 | 3.28 | 3.30 | n/m | ||||||
| Shares, m | — | — | — | — | — | 16 | 3 | 1 | 38 | 51 | 64 | +34.1% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | 0 | (1) | (25) | (48) | (99) | (103) | n/m | |||||
| Capex | — | — | — | — | — | 0 | 0 | 0 | (1) | (1) | (1) | n/m | ||||||
| Free cash flow | — | — | — | — | — | 0 | (1) | (25) | (49) | (101) | (104) | n/m | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | 1 | 0 | 80 | 233 | 169 | 251 | +241.9% | |||||
| Net debt | — | — | — | — | — | (1) | 0 | (72) | (216) | (178) | (241) | +259.4% | ||||||
| Shareholders’ equity | — | — | — | — | — | (2) | (4) | 72 | 273 | 168 | 230 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | (0.34) | 0.04 | (95.65) | (27.70) | (44.05) | (48.84) | (43.7) pt | |||||
| ROIC | — | — | — | — | — | 0.00 | 0.00 | (15,511.90) | (68.69) | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | 0.00 | (0.08) | (306.36) | (31.96) | (53.28) | (60.50) | (53.3) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | 2 | 33 | 57 | 82 | — | +244.8% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 2 Nov 2026
enGene Therapeutics Inc vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CHRS Coherus Oncology, Inc. | $115.7M | — (loss-making) | — (loss-making) | +39.53% (above 0%: growing) | n/m | −33.15% (below 0%: shrinking) | 70.35% | (225.98%) | Compare |
| PYPD PolyPid Ltd. | $115.2M | — (loss-making) | — | — | n/m | −64.96% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| FHTX Foghorn Therapeutics Inc. | $113.1M | — (loss-making) | — (loss-making) | +112.68% (above 0%: growing) | n/m | +14.88% (above 0%: growing) | 100.00% | (54.78%) | Compare |
| ENGN enGene Therapeutics Inc | $112.6M | — (loss-making) | — | — | n/m | +28.07% (above 0%: growing) | — | 0.00% | |
| NKTX Nkarta, Inc. | $112.5M | — (loss-making) | — | — | n/m | −29.19% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CDXS Codexis, Inc. | $111.7M | — (loss-making) | — (loss-making) | −2.69% (below 0%: shrinking) | n/m | +48.60% (above 0%: growing) | 76.45% | (75.29%) | Compare |
| ARMP Armata Pharmaceuticals, Inc. | $111.5M | — (loss-making) | — (loss-making) | +15.72% (above 0%: growing) | n/m | −17.98% (below 0%: shrinking) | 100.00% | (410.84%) | Compare |
| HUMA Humacyte, Inc. | $109.9M | — (loss-making) | — (loss-making) | +34.88% (above 0%: growing) | n/m | +17.85% (above 0%: growing) | (203.20%) | (6,649.26%) | Compare |
| NERV Minerva Neurosciences, Inc | $109.8M | — (loss-making) | — (loss-making) | — | n/m | −553.48% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $112.1M | — | — | +34.88% | — | −23.58% | 35.18% | (65.03%) |
Pay and ownership Proxy statement filed 8 May 2026
Ownership
Directors and executive officers, together
10.50% of the votes
Forbion Growth
13.20% of the votes
Perceptive Advisors LLC and affiliates
9.90% of the votes
Venrock Healthcare Capital Partners III, L.P. and affiliates
7.10% of the votes
Invus and affiliates
6.70% of the votes
Deep Track Biotechnology Master Fund, Ltd. and affiliates
6.40% of the votes
Lumira Ventures III, L.P. and affiliates
6.20% of the votes
Gerald Brunk
6.20% of the votes
Cormorant Asset Management, LP
5.90% of the votes
Forbion Capital Fund III Coöperatief U.A.
5.00% of the votes
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement